EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Efficacy and Safety of Tegoprazan‐Based Dual, Triple, and Quadruple Therapies in First‐Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial

Yu-Cheng Zhu, Keng Li, Anjiang Sun, Sihui Lin, Jun Zhang, Shanshan Meng, Xin Xia, Hong Gao, Juan Lin, Wei Jiang iD

Helicobacter · 2026-05 · 31 (3)

DOI: 10.1111/hel.70147 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, online erschienen am 11.06.2026. Verfasst von Yu-Cheng Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Anti-Bacterial Agents, Helicobacter pylori. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Xiamen Public Hospital Reform and High-quality Development Demonstration Project, Xiamen Key Medical and Health Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Resistance to antibiotics has resulted in the effectiveness of conventional eradication therapies for Helicobacter pylori being reduced, creating a need for regimens that are effective, safe, and simple. In this study, we evaluated the eradication efficacy, adverse events, and medication adherence of four different tegoprazan‐based regimens administered as first‐line therapy for H. pylori infection. We also explored the clinical value of adding bismuth to a triple therapy regimen.

Methods

In this prospective, randomized controlled trial, 640 treatment‐naive patients with confirmed H. pylori infection were randomly assigned to one of the four groups undergoing 14‐day treatment regimens of tegoprazan–amoxicillin (TA), tegoprazan–tetracycline (TT), tegoprazan–amoxicillin–tetracycline (TAT), or tegoprazan–amoxicillin–tetracycline–bismuth (TATB), with 160 patients in each group. The outcomes were the eradication rate, incidence of adverse events, and medication adherence.

Results

In the intention‐to‐treat analysis, the H. pylori eradication rates in the TA, TT, TAT, and TATB groups were 80.0% (95% confidence interval [CI]: 73.0–85.9), 61.9% (95% CI: 53.9–69.4), 93.1% (95% CI: 88.0–96.5), and 89.4% (95% CI: 83.5–93.7), respectively. Compared with the TATB regimen, the TAT regimen was non‐inferior (95% CI, −3.9% to 11.5%; non‐inferiority p < 0.001), whereas demonstrating non‐inferiority in the TA and TT regimens failed. Adverse events were less frequent in the TA (10.6%), TT (17.5%), and TAT (20.0%) groups than in the TATB group (36.9%; all p < 0.001). Medication adherence was high across groups, with no significant between‐group differences observed.

Conclusions

High eradication efficacy was demonstrated for the TAT regimen; this regimen was non‐inferior to the TATB regimen, and it was associated with fewer adverse events. These findings suggest that it may be an effective first‐line treatment option for H. pylori infection. Trial Registration ClinicalTrials.gov identifier: NCT06977841

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter InfectionsAnti-Bacterial AgentsHelicobacter pyloriHumansDrug Therapy, CombinationFemaleProspective StudiesTetracyclineMiddle AgedMaleTreatment OutcomeAdultAmoxicillinAgedBismuth

Stichwörter der Autor:innen

Helicobacter pyloriamoxicillineradication therapytegoprazantetracycline

Substanzen

Anti-Bacterial AgentsTetracyclineAmoxicillinBismuth

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China.
  • State Key Laboratory of Cellular Stress Biology, Cancer Research Center, School of Medicine, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.
  • State Key Laboratory of Vaccines for Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.
  • Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.

ORCID-Profile: Wei Jiang

Förderung

  • Xiamen Public Hospital Reform and High-quality Development Demonstration Project
  • Xiamen Key Medical and Health Project

Zitieren

APA

Zhu, Y. C., Li, K., Sun, A., Lin, S., Zhang, J., Meng, S., Xia, X., Gao, H., Lin, J., & Jiang, W. (2026). Efficacy and Safety of Tegoprazan‐Based Dual, Triple, and Quadruple Therapies in First‐Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial. Helicobacter, 31(3). https://doi.org/10.1111/hel.70147

Vancouver

Zhu YC, Li K, Sun A, Lin S, Zhang J, Meng S, et al. Efficacy and Safety of Tegoprazan‐Based Dual, Triple, and Quadruple Therapies in First‐Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial. Helicobacter. 2026;31(3). doi:10.1111/hel.70147

BibTeX
@article{Zhu2026,
  author = {Zhu, Yu-Cheng and Li, Keng and Sun, Anjiang and Lin, Sihui and Zhang, Jun and Meng, Shanshan and Xia, Xin and Gao, Hong and Lin, Juan and Jiang, Wei},
  title = {Efficacy and Safety of Tegoprazan‐Based Dual, Triple, and Quadruple Therapies in First‐Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial},
  journal = {Helicobacter},
  year = {2026},
  volume = {31},
  number = {3},
  doi = {10.1111/hel.70147}
}
Kostenlos starten →